Literature DB >> 6135482

Limitations of immune complex measurements in colorectal disease.

J Hobbiss, K M Cooper, M Moore, E Gowland, P F Schofield.   

Abstract

Three techniques (Clq, Raji and L1210 binding assays) alleged to measure circulating immune complexes (ICs) were applied to the sera of 101 patients with colorectal disease (54 carcinoma; 23 inflammatory; 13 benign tumour and 11 miscellaneous) at the time of diagnostic or definitive surgery, and 58 healthy adult controls. Elevated levels in the pathological sera were observed by all 3 methods in order of sensitivity: Raji greater than Clq greater than L1210. However, none of them differentiated between benign, inflammatory and neoplastic conditions nor, in the case of colorectal carcinoma, was there any correlation with stage of disease. With the exception of Raji v. L1210 (r = 0.43, P less than 0.001), correlations between the various assays were poor and levels of serum carcinoembryonic antigen (CEA) did not correlate with ICs measured by any of the techniques. Indeed, the IC assays were even less discriminatory than CEA, which was elevated mainly in the serum of carcinoma patients and which was positively correlated with serum gamma-glutamyl transpeptidase (gamma GT) (r = 0.42, P less than 0.005). The data suggest that the lack of concordance between the IC assays is a reflection of heterogeneity among ICs, interfering factors present in pathological sera, or both. Thus the IC assays deployed here have neither diagnostic nor prognostic utility in colorectal disease at this time, and immunochemical characterization of the serum reactive material detected by the different assays is required.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135482     DOI: 10.1002/bjs.1800700808

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Absence of complement fixing antibodies against lipopolysaccharides from Escherichia coli in a subgroup of patients with Crohn's disease.

Authors:  M Zeitz; U Hope; B Wust; C Galanos; B Möller; T J Lawley; E O Riecken
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

2.  Serial circulating immune complex values and development of metastatic disease in breast cancer and malignant melanoma patients.

Authors:  Z Ronai; J Shaham; J Stein; D Sulitzeanu
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancer.

Authors:  K A Chester; R H Begent
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.